Abstract Search

ea0073aep509 | Pituitary and Neuroendocrinology | ECE2021

Self-administration of long-acting somatostatin analogues in NET patients forced by the COVID-19 pandemic – does it affect the clinical outcome?

Opalinska Marta , Anna Kurzynska , Staszczak Anna Sowa , Joanna Palen-Tytko , Zwinczewska Helena , Karolina Morawiec-Slawek , Hubalewska-Dydejczyk Alicja

BackgroundSomatostatin analogues (SSA) (octreotide and lanreotide) are recommended as a first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of them are usually used in injection repeated every 4 weeks.The study objectiveWas to compare the way of SSA administration (injection performed by profession...

0 shares

ea0099p311 | Endocrine-Related Cancer | ECE2024

The impact of primary tumor site on clinical manifestation and prognosis of ectopic Cushing’s syndrome (ECS). Do pulmonary neuroendocrine tumors stand out?

Gamrat Aleksandra , Minasyan Mari , Komisarz-Calik Maria Aleksandra , Rzepka Ewelina , Paleń-Tytko Joanna , Opalinska Marta , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: Ectopic Cushings syndrome (ECS) is a rare disease with limited and error-prone published data on the epidemiology, clinical presentation and diagnosis of ECS.Objectives: This study aims to examine the clinical course of patients with ECS in relation to the primary tumor localization.Methods: Thirty-five consecutive ECS patients at a tertiary clinical center were analyzed. The clinical, biochemical (including CRH...

0 shares

Endocrine Abstracts

Self-administration of long-acting somatostatin analogues in NET patients forced by the COVID-19 pandemic – does it affect the clinical outcome?

The impact of primary tumor site on clinical manifestation and prognosis of ectopic Cushing’s syndrome (ECS). Do pulmonary neuroendocrine tumors stand out?

BiosciAbstracts